Results 61 to 70 of about 18,247 (232)

Pathological Mechanism‐Inspired Biomimetic Nano‐Senotherapy for Reversing Experimental Atherosclerosis in ApoE−/− Mice

open access: yesAdvanced Science, EarlyView.
The biomimetic self‐assembly nanomedicine reversing atherosclerosis via senotherapy strategy. ABSTRACT The greatest challenge in atherosclerosis (AS) management lies in achieving lesion reversal, not merely slowing progression. Senescent cell accumulation—driven by continuous generation and apoptotic resistance—perpetuates plaque pathology and ...
Yuhan Tian   +9 more
wiley   +1 more source

Egr-1 induces a profibrotic injury/repair gene program associated with systemic sclerosis. [PDF]

open access: yesPLoS ONE, 2011
Transforming growth factor-ß (TGF-ß) signaling is implicated in the pathogenesis of fibrosis in scleroderma or systemic sclerosis (SSc), but the precise mechanisms are poorly understood. The immediate-early gene Egr-1 is an inducible transcription factor
Swati Bhattacharyya   +7 more
doaj   +1 more source

Impact of Evolving Treatment Patterns on Interstitial Lung Disease Progression in Systemic Sclerosis Using the European Scleroderma Trials and Research Database

open access: yesArthritis &Rheumatology, EarlyView.
Objective The treatment landscape for systemic sclerosis‐associated interstitial lung disease (SSc‐ILD) has evolved with increasingly available immunosuppressive therapies (ISTs) and antifibrotic treatments. However, their real‐world use remains unclear.
Corrado Campochiaro   +17 more
wiley   +1 more source

Noncompaction on scleroderma

open access: yes, 2016
International audienceWe read with interest the case report by Kalayci etal. about a 40-year-old female with diffuse cutaneoussclerosis (scleroderma) in whom left ventricularhypertrabeculation/noncompaction (LVHT) was detectedupon echocardiographic ...
Finsterer, Josef, Zarrouk-Mahjoub, Sinda
core   +1 more source

A Unique Presentation of Anti-RNA Polymerase III Positive Systemic Sclerosis Sine Scleroderma

open access: yesCase Reports in Rheumatology, 2016
Systemic sclerosis is a rare autoimmune disorder with a wide spectrum of clinical manifestations and a multitude of autoantibodies that are associated with it.
Cody M. Lee   +4 more
doaj   +1 more source

Interstitial Lung Disease in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: A European Multicenter Study

open access: yesArthritis &Rheumatology, EarlyView.
Objective Interstitial lung disease (ILD) can occur in association with antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV‐ILD) or as an isolated entity with positive ANCA (ANCA‐ILD). However, data on the epidemiology and outcomes of these conditions remain limited.
Aglaia Chalkia   +18 more
wiley   +1 more source

Long Noncoding RNA H19 Mediates STAT3‐Dependent Activation of Keratinocytes and Fibroblasts in Systemic Sclerosis Skin

open access: yesArthritis &Rheumatology, EarlyView.
Objective Dermal systemic sclerosis (SSc) fibroblasts and their exosomes can activate keratinocytes in SSc, with long noncoding RNA (lncRNA) H19 highlighted as the most up‐regulated RNA in their cargo compared with healthy controls (HCs). The role of H19 in SSc pathogenesis has never been investigated.
Begoña Caballero‐Ruiz   +3 more
wiley   +1 more source

Lung Ultrasound for the Detection of Radiologic Progression of Interstitial Lung Abnormalities in Patients With Rheumatoid Arthritis

open access: yesArthritis &Rheumatology, EarlyView.
Objective Interstitial lung disease (ILD) is an important extra‐articular manifestation of rheumatoid arthritis (RA) associated with high mortality and morbidity. Lung ultrasonography (LUS) has recently emerged as a possible screening tool. We assessed the role of LUS in monitoring radiologic progression and the development of new interstitial lung ...
Marie Vermant   +15 more
wiley   +1 more source

Heparan sulfate-dependent ERK activation contributes to the overexpression of fibrotic proteins and enhanced contraction by scleroderma fibroblasts

open access: yes, 2008
Objective. To investigate the contribution of heparan sulfate proteoglycan and Ras/MEK/ERK to the overexpression of profibrotic proteins and the enhanced contractile ability of dermal fibroblasts from patients with systemic sclerosis (SSc; scleroderma ...
Wilcox-Adelman, S   +29 more
core   +1 more source

Integrated Clinical and Proteomic Profiling of CD19 Chimeric Antigen Receptor T Cell Therapy in Progressive Systemic Sclerosis

open access: yesArthritis &Rheumatology, EarlyView.
Objective To characterize the clinical, immunologic, and proteomic changes associated with CD19 chimeric antigen receptor T cell therapy in patients with progressive systemic sclerosis (SSc). Methods Patients with progressive SSc received CD19 chimeric antigen receptor (CAR)‐T cell therapy and were observed longitudinally for safety, clinical efficacy,
Chenhan Jia   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy